Company intelligence / Profile preview
NexEos Bio
Pottstown, Pennsylvania, United Statesnexeosbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NexEos Bio is developing a non-invasive imaging agent, NDX-3324, for diagnosing and monitoring EoE. They also have therapeutic programs targeting eMBP1 for various eosinophil-mediated diseases.
- Therapeutic areas
- GastroenterologyOphthalmology
- Modalities
- Non-invasive imaging agentsTherapeutic programs targeting binding & neutralization of eMBP1
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Collaborations with NIHAltitude Lab
Beyond the preview
Go deeper on NexEos Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NexEos Bio.